Merrimack | Jotup

Merrimack Reports Third Quarter 2023 Financial Results

Retrieved on:

Thursday, November 2, 2023

Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Irinotecan, Food, Oxaliplatin, Medication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seribantumab, Shanda, Merrimack, Ipsen, Investment, Pharmaceutical industry

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023.
General and administrative expenses for the third quarter ended September 30, 2023, were $531 thousand, compared to $504 thousand for the same period in 2022.
As of September 30, 2023, Merrimack had short term investments and cash and cash equivalents of $18.9 million, compared to $19.4 million as of December 30, 2022.
As of September 30, 2023, Merrimack had 14.3 million shares of common stock outstanding.

MNA: Dana-Farber Merrimack Valley Nurses to Leaflet Outside Boston Hospital September 29 about DFCI Spending Money on Lock Out After Strike Instead of Investing in Nurses and Cancer Patients

Retrieved on:

Thursday, September 28, 2023

BOSTON, Sept. 28, 2023 /PRNewswire/ -- During a lockout inflicted on Merrimack Valley nurses and patients by Dana-Farber Cancer Institute (DFCI) following a one-day strike, nurses will meet outside the DFCI hospital in Boston on Friday, September 29 to leaflet the public and share their concerns about how Dana-Farber executives are spending critical resources.

Key Points:

DFCI – MV nurses and nurse practitioners held a one-day strike on September 27 because DFCI executives refused to make reasonable compromises with nurses to reach a fair contract.
Instead of reaching a reasonable compromise with nurses, DFCI is refusing to let nurses back to work following the strike.
DFCI executives are spending money on travelers rather than allowing local nurses to care for their patients.
DFCI is disaffiliating from Brigham and Women's Hospital and spending millions on a new inpatient hospital.

Merrimack Reports Second Quarter 2023 Financial Results

Retrieved on:

Thursday, August 3, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023.
Interest income in the second quarter ended June 30, 2023, was $178 thousand compared to $8 thousand for the same period in 2022.
General and administrative expenses for the second quarter ended June 30, 2023, were $569 thousand, compared to $486 thousand for the same period in 2022.
In January 2023, Ipsen presented clinical trial results at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Merrimack Reports First Quarter 2023 Financial Results

Retrieved on:

Thursday, May 4, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.
Interest income in the first quarter ended March 31, 2023, was $176 thousand compared to no interest income for the same period in 2022.
As of March 31, 2023, Merrimack had cash and cash equivalents of $19.4 million, compared to $19.4 million as of December 31, 2022.
In January 2023, Ipsen presented clinical trial results at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Merrimack Reports Full Year 2022 Financial Results

Retrieved on:

Thursday, March 9, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.
Merrimack reported a gain on sale of assets for the year ended December 31, 2022, of $0.4 million compared to $0.1 million for the same period in 2021.
As of December 31, 2022, Merrimack had 14.2 million shares of common stock outstanding.
In the August 2022 announcement, Ipsen reported that the clinical study results would be communicated with the regulatory agency.

Merrimack Reports Full Year 2020 Financial Results

Retrieved on:

Wednesday, March 10, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Merrimack Pharmaceuticals, Merrimack, New Hampshire, Merrimack, NASDAQ, Finance, Financial markets, Companies

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its full year 2020 financial results for the period ended December 31, 2020.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its full year 2020 financial results for the period ended December 31, 2020.
As of December 31, 2020, Merrimack had cash and cash equivalents and investments of $14.0 million, compared to $16.6 million as of December 31, 2019.
As of December 31, 2020, Merrimack had 13.4 million shares of common stock outstanding.
On February 11, 2021 Ipsen released its full year 2020 financial results.

North American Partners in Anesthesia Expands Anesthesia Services to Lawrence General Hospital in Lawrence, Massachusetts

Retrieved on:

Tuesday, January 19, 2021

Cities in the United States, Regions of the United States, Geography of Massachusetts, North Andover, Massachusetts, Merrimack Valley, Andover, Massachusetts, Lawrence, Massachusetts, Methuen, Massachusetts, Merrimack, Anesthesia, Andover station, McGovern Transportation Center

MELVILLE, N.Y., Jan. 19, 2021 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) is growing its New England regional service area with a new clinical partnership at Lawrence General Hospital.

Key Points:

MELVILLE, N.Y., Jan. 19, 2021 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) is growing its New England regional service area with a new clinical partnership at Lawrence General Hospital.
Lawrence General Hospital provides acute and elective care to families throughout the Merrimack Valley region of Massachusetts and southern New Hampshire.
As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day.
It offers services from its main campus in Lawrence, as well as from locations in Andover, North Andover, Methuen, MA and Salem, NH.

Merrimack Reports Third Quarter 2020 Financial Results

Retrieved on:

Thursday, November 5, 2020

Biotechnology, Pharmaceutical, Health, Balance sheet, Companies, Merrimack Pharmaceuticals, Merrimack, Cash and cash equivalents, BlackBerry Limited

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its third quarter 2020 financial results for the period ended September 30, 2020.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its third quarter 2020 financial results for the period ended September 30, 2020.
General and administrative expenses for the third quarter ended September 30, 2020 were $1.0 million, compared to $4.3 million for the same period in 2019.
As of September 30, 2020, Merrimack had cash and cash equivalents and investments of $15.8 million, compared to $16.6 million as of December 31, 2019.
- On October 22, 2020 Ipsen released its third quarter financial results.

In New Book "Awakening Awe - An Illustrated Journey to Reverence" Dr. Mary Baures Challenges the Mindset that Brought Us the Coronavirus

Retrieved on:

Thursday, September 24, 2020

Articles, Emotions, Awe, Fear, Reverence, Merrimack

Her new book Awakening Awe An illustrated Journey Toward Reverence extends her plea against using our brother and sister species as commodities.

Key Points:

Her new book Awakening Awe An illustrated Journey Toward Reverence extends her plea against using our brother and sister species as commodities.
Dr. Baures says the coronavirus was just a starter pandemic, a warning shot.
Her new book, published through Merrimack Media, asks us to be the change the world needs.
The book is available now on Amazon and through the author's website ( https://marybauresbooks.com ).

Merrimack Reports Second Quarter 2020 Financial Results

Retrieved on:

Friday, August 7, 2020

Biotechnology, Pharmaceutical, Health, Clinical trials, Merrimack

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its second quarter 2020 financial results for the period ended June 30, 2020.

Key Points:

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its second quarter 2020 financial results for the period ended June 30, 2020.
In addition, Merrimack made continued progress in reducing our operating expenses during the second quarter of 2020, and we expect to see continued reductions during the second half of 2020.
No research and development expenses were recognized for the second quarter ended June 30, 2020 compared to $4.7 million for the same period in 2019.
General and administrative expenses for the second quarter ended June 30, 2020 were $1.2 million, compared to $5.9 million for the same period in 2019.